DBV Technologies S.A. (NASDAQ:DBVT)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
DBVT Weekly Chart

Old Forum Content for DBVT

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • debeers: $DBVT- .News you can use DBVT, +15.66%; Says product candidate shows more success reducing peanut sensitivity in children. FDA ruling. Short form: peanut allergy in kids is scary because so much food has some peanut powder in it.
  • issues: Shares of biotech companies Karyopharm Therapeutics ($KPTI) and DBV Technologies ($DBVT) jumped Friday after the former gained approval for a cancer treatment. In morning trading on the stock market today, Karyopharm stock popped 2.8%, near 9.20, in huge volume. DBV stock soared 15.5%, near 10.90, in higher-than-average volume. It wasn't immediately clear why shares of DBV flew higher Friday morning. Karyopharm gained Food and Drug Administration approval for a multiple myeloma drug in patients who've worsened while taking at least four other cancer treatments. The FDA sped up approval of Karyopharm's drug, Xpovio, due to robust responses in clinical studies.
  • steve71: @issues $KPTI $DBVT $DBVT up on news that it will once again attempt to file BLA with FDA for their marginally effective product. A Sell opportunity.
  • issues: @steve71 $KPTI $DBVT Agreed. We passed on buying either. NP
  • efrain007: $DBVT $GTHX $SPPI some biotechs down big on news, watching for a trade.
  • steve71: $AIMT $DBVT $ANAB Aimmune has two halfway significant competitors in the race to get a peanut allergy treatment to market. And then there was one. $DBVT is down 50% on the day on news that they have withdrawn their Biologic License Application ( ...
  • woodman: @steve71 $TWTR $AIMT - I read that. I have a nut allergy. I think of the growing number of kids with food allergies and schools with nut-free classrooms, etc., and I think about the size of the market potentially. And they could dominate that market along with one other company (DVB Technologies, ticker $DBVT) . Some links: https://www.investors.com/news/technology/this-biotech-could-have-a-blockbuster-should-it-partner-with-big-pharma/ https://www.xconomy.com/san-francisco/2018/02/20/aimmunes-peanut-allergy-drug-hits-study-goals-fda-filing-planned/ https://www.drugdevelopment-technology.com/comment/dbv-aimmune-poised-dominate-peanut-allergy-market/
  • gwenzee: @woodman $TWTR $AIMT $DBVT At first I thought you were referring to the "nuts" in SMM.
  • steve71: @woodman $TWTR $AIMT $DBVT A few weeks old, but here's a brief note on $DBVT. "Rival DBV Technologies vaccine had much weaker results, with only a 12% separation from placebo. Still will seek FDA approval." Adam Feuerstein looked at $DBVT results and asked, "Why bother to do clinical trials if you're going to ignore bad results and submit anyway?"
  • woodman: @steve71 $TWTR $AIMT $DBVT - Interesting. Thanks.
  • woodman: @gwenzee $TWTR $AIMT $DBVT -- LOL. Yeah, that too....
  • mradams0621: ...
    $DBVT Dbv Technologies ... 37.00 6.66%
    $RUSL Direxion Daily Ru... 17.54 6.43%

    down gapers:

    $SKLN Skyline Medical I... 2.50 -41.31%
    $EMSA ipath Short Enhan... 91.96 -22.47%
    $LPCN Lipocine Inc 12.27 -7.12%
    $PLNT Planet Fitness In... 15.00 -6.4 ...
  • pcotton: ...
    IPOs I'm watching: $ADMS $AFMD $ANET $AXTA $BLUE $CLLS $CYBR $DBVT $ERI $GNCA $GWB $HAWK $INO $IPO $LPCN $MBLY $NCLH $NDRM $NGHC $NSTG $NVAX $OPB $PIRS $PTLA $PYPL $RARE $RH $SERV $SPY $SYF $TERP $TSE $VDSI $W $XNCR $XOM
    My notes on IPOs:
    ADMS - Ad ...
  • pcotton: ...
    $AVOL $CONE $CYBR $DBVT $FCB $FIT $HUBS $IBP $INCR $LPCN $MBLY $NDRM $OPB $PIRS $PRAH $PTLA $PYPL $RDUS $SYF $TSE $XNCR

    My current watchlist:
    $AAOI $BFAM $CARA $CHRS $CMRX $DBVT $DPLO $EGRX $ERI $GLOB $GWB $HAWK $IBP $JRVR $LOXO $NCLH $OPB $Q $RH $ ...
Visit the Trading Forum to join in the discussion.
Stock Price $0.74
Change -2.83%
Volume 11,461

DBV Technologies SA is an epicutaneous immunotherapy company. The Company is engaged in research and development of patient-friendly therapy for food and pediatric allergy patients.

Request Video of DBVT
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!